Actemra IV (tocilizumab) / JW Pharma, Roche  >>  Phase 1
Welcome,         Profile    Billing    Logout  

47 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Actemra IV (tocilizumab) / Roche, JW Pharma
jRCT2080223801: A PHASE I STUDY OF RO7030816 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Recruiting
1
77
Japan
Lunsumio (mosunetuzumab) - Roche, Biogen, Actemra IV (tocilizumab) - Roche, JW Pharma, lenalidomide - Generic mfg.
CHUGAI PHARMACEUTICAL CO., LTD.
B-cell non-Hodgkin's lymphoma, follicular lymphoma
 
 
jRCT2080224729: A PHASE I STUDY OF ERY974 AS A SINGLE AGENT IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS

Recruiting
1
39
Japan
ERY-974 - Roche, Actemra IV (tocilizumab) - Roche, JW Pharma
Chugai Pharmaceutical Co., Ltd.
Advanced/recurrent solid tumors
 
 
jRCT2080225077: A PHASE I STUDY OF RO7082859 IN PATIENTS WITH B-CELL NON-HODGKIN'S LYMPHOMA

Completed
1
12
Japan
Columvi (glofitamab) - Roche, Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Actemra IV (tocilizumab) - Roche, JW Pharma
Chugai Pharmaceutical Co., Ltd.
 
 
ChiCTR1900021808: A Phase 1, Randomized, Double-Blind and Paralle, Controlled Single-dose Clinical Trial of Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of QX003S and Tocilizumab in Chinese Health Male Subjects

Recruiting
1
86
 
8 mg/kg QX003S ;Tocilizumab, 8 mg/kg
JiangSu Qyuns Therapeutics Co., Ltd; First Hospital of Jilin University, At sponsor's own expense
Active rheumatoid arthritis
 
 
ACTRN12618000859280: Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)

Active, not recruiting
1
190
 
Mycenax Biotech Inc., Mycenax Biotech Inc.
Elevated liver enzymes, neutropenia, thrombocytopenia
 
 
ChiCTR1800015396: A Randomized, Double-blinded, Single-dose, 3-arm Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT1806 Injection vs Actemra in Healthy Chinese Male Subjects

Not yet recruiting
1
138
 
BAT1806 4mg/kg ;Actemra-Eu 4mg/kg ;Actemra-Us 4mg/kg
The First Bethune Hospital of Jilin University; Level of the institution：, self-funding
RA
 
 
HS628-BE, ChiCTR2000032146: Domestic Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection (HS628) and the innovative drug Actemra: a single-center, randomized, double-blind, parallel-controlled phase I clinical trial

Completed
1
80
 
A single drug delivery
Shanghai Xuhui District Central Hospital; Hisun Pharmaceutical (Hangzhou) Co., Ltd., Fully self-raised
Rheumatoid arthritis; Systemic juvenile idiopathic arthritis
 
 
TC19LGH, NCT04560205: Tocilizumab in COVID-19 Lahore General Hospital

Recruiting
1
50
RoW
Tocilizumab, ACTEMRA®
Lahore General Hospital
SARS-CoV Infection
12/20
12/20
ChiCTR2000030365: Comparative study for the pharmacokinetics and safety of IA001 injection and Actemra in healthy male volunteers

Not yet recruiting
1
90
 
Comparing Topiramab (IA001 injection) produced by two companies
Hospital affiliated to Changchun University of Traditional Chinese Medicine; Liaoning Grand Nuokang Biopharmaceutical Co., Ltd, Completely self raised
Rheumatoid arthritis
 
 
NCT04070781: Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

Terminated
1
1
US
Itacitinib, Itacitinib adipate, Tocilizumab, Actemra
Columbia University, Incyte Corporation
Steroid Refractory GVHD, Graft Vs Host Disease
12/21
12/21
ACTRN12621000663853: A single dose phase 1 study to evaluate safety and Pharmacokinetics of three tocilizumab products in normal healthy volunteers

Completed
1
300
 
Dr. Reddy’s Laboratories Ltd., Biologics, Dr. Reddy’s Laboratories Ltd., Biologics
Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA)
 
 
NCT05118737: Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

Recruiting
1
230
RoW
Colchicine, Colcrys
Hamad Medical Corporation
COVID-19 Pneumonia
04/22
08/22
NCT05188378: A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects

Recruiting
1
300
RoW
CT-P47, EU-approved RoActemra,
Celltrion
Healthy Subjects
10/22
01/23
YO42610, NCT04657302: A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed
1
30
RoW
Obinutuzumab, Glofitamab, Tocilizumab
Hoffmann-La Roche
Lymphoma
10/22
01/24
Tocilam, NCT04547062: Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

Completed
1
12
Europe
Tocilizumab
Nantes University Hospital
Acute Myeloid Leukemia (AML)
04/23
04/23
NCT05333302: Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Recruiting
1
10
RoW
CD19 CAR-T-cells, Tocilizumab, Actemra
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
12/24
06/25
NCT05129280: A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Terminated
1
23
Europe, US, RoW
RO7444973, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Solid Tumors
07/23
07/23
NCT05968508: A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects

Active, not recruiting
1
300
RoW
BAT1806 prefilled subcutaneous injection/RoActemra® (from EU)
Bio-Thera Solutions
Healthy Men
12/24
04/25
NCT06016179: Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Recruiting
1
12
US
Tocilizumab, Actemra
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Malignant Pleural Effusion, Malignant Ascites
01/26
01/27
ISRCTN17975931: A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma

Recruiting
1
36
Australia, Belgium, Denmark, Italy, Poland, Spain, US
Gazyva (obinutuzumab) - Roche, Biogen, Nippon Shinyaku, Columvi (glofitamab) - Roche, dexamethasone - Generic mfg., Actemra IV (tocilizumab) - Roche, JW Pharma, Actemra SC (tocilizumab SC) - Roche, Halozyme
Genentech, Inc;Genentech, Genentech
B-cell non-Hodgkin lymphoma
 
 
LUSZ_CTS_COVID, NCT05925140: LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

Recruiting
1
1000
RoW
Lopinavir / Ritonavir, Kaletra, Remdesivir (RDV), Veklury, Tocilizumab, Actemra, Corticosteroid Therapy-enhanced Standard Care (CTSC), CTSC
Lebanese University, Hospital Saydet Zgharta University Medical Center
COVID-19, Hospitalized COVID-19 Patients
12/24
12/25
NCT02874573: Tocilizumab in Schizophrenia

Recruiting
1
20
US
Tocilizumab, Actemra, Normal saline, 0.9% NS
Brian Miller, Brain & Behavior Research Foundation
Schizophrenia, Psychotic Disorders
12/23
12/23
NL-TCZ-12280, NCT06262477: A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Recruiting
1
300
US
BIIB800, BAT1806, Actemra, Tocilizumab, RoActemra
Biogen
Healthy Volunteer
11/24
11/24
NCT03866239: A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Terminated
1
47
Europe, US
Obinutuzumab, Gazyva/Gazyvaro, Atezolizumab, Tecentriq, Cibisatamab, Tocilizumab
Hoffmann-La Roche
Colorectal Cancer
03/24
03/24
ChiCTR2300075487: A randomised, double-blind, single dose, parallel two-arm study of the pharmacokinetics and safety of BAT1806 subcutaneous injection versus ACTEMRA® in healthy male subjects in China

Not yet recruiting
1
150
 
BAT1806 subcutaneous injection group; ACTEMRA (EU) group
Drug Clinical Trial Research Center, The Second Affiliated Hospital of Anhui Medical University; Bio-Thera Solutions, Ltd., Bio-Thera Solutions, Ltd.
Rheumatoid arthritis
 
 
NCT03448042: A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Active, not recruiting
1
537
Europe, Canada, Japan, US, RoW
Runimotamab, BTRC4017A, RO7227780, Trastuzumab, Tocilizumab
Genentech, Inc.
Solid Tumors
05/25
05/25
GO43693, NCT05364424: A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Active, not recruiting
1
40
US
Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma (DLBCL)
12/26
12/26
NCT04007029: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Recruiting
1
24
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell therapy, Chimeric Antigen Receptor T-cell Infusion, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP (cyclophosphamide) monohydrate, CTX (cytoxan), CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP fludarabine: 2-Fluoroadenine 9-beta-D-Arabinofuranoside 5'-Monophosphate, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Tocilizumab, Actemra, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA (myeloma receptor antibody), R-1569, RoActemra
Jonsson Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy
CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
08/25
08/26
CAMMA 1, NCT04910568: A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
1
184
Europe, Canada, Japan, US, RoW
Cevostamab, Tocilizumab, Actemra/RoActemra, Pomalidomide, Daratumumab, Dexamethasone
Genentech, Inc., Hoffmann-La Roche
Multiple Myeloma
09/24
07/25
NCT05155345: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

Active, not recruiting
1
50
Europe, US, RoW
Mosunetuzumab, Tocilizumab
Hoffmann-La Roche
Systemic Lupus Erythematosus
09/24
06/25
NCT05022927: A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Active, not recruiting
1
179
Japan, RoW
ERY974, Tocilicumab, Atezolizumab, Bevacizumab
Chugai Pharmaceutical
Hepatocellular Carcinoma (HCC)
12/25
12/25
NCT06372574: A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Withdrawn
1
210
NA
RO7617991, Tocilizumab, Actemra®, RoActemra®, RO4877533
Genentech, Inc.
Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
02/28
02/28
NP40126, NCT03467373: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Checkmark Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Dec 2022 - Dec 2022: Safety and efficacy of phase 1 study in combination with R-CHOP in patients with previously untreated DLBCL
Active, not recruiting
1
172
Europe, Canada, US, RoW
Glofitamab, RO7082859, Obinutuzumab (G), Gazyva, Rituximab (R), Rituxan, Tocilizumab, Actemra, Cyclophosphamide, Doxorubicin, Vincristine, Oncovin, Prednisone, Polatuzumab vedotin
Hoffmann-La Roche
B-Cell Lymphoma, Non-Hodgkin Lymphoma
10/24
10/24
NCT03970226: Tocilizumab in Children With ACP

Recruiting
1
27
US
Tocilizumab, Actemra
University of Colorado, Denver, National Cancer Institute (NCI)
Adamantinomatous Craniopharyngioma
12/24
12/25
NCT05164133 / 2021-005332-27: A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19

Completed
1
2
Europe, US, RoW
Tocilizumab
Hoffmann-La Roche
COVID-19
03/24
03/24
BP43131, NCT05219513: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated
1
53
Europe, US, RoW
RO7443904, Glofitamab, RO7082859, Obinutuzumab, Tocilizumab, Actemra
Hoffmann-La Roche
Lymphoma, Non-Hodgkin
07/24
07/24
NCT05619744: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Recruiting
1
168
Europe, Japan, US
RO7616789, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Small Cell Lung Cancer, Neuroendocrine Carcinoma
09/25
09/25
GO39775, NCT03275103: Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Checkmark Data from trial for r/r multiple myeloma at ASH 2022
Dec 2022 - Dec 2022: Data from trial for r/r multiple myeloma at ASH 2022
Checkmark Data from trial for r/r multiple myeloma at ASH 2021
Dec 2021 - Dec 2021: Data from trial for r/r multiple myeloma at ASH 2021
Recruiting
1
420
Europe, Canada, US, RoW
Cevostamab, BFCR4350A; RO7187797, Tocilizumab, Actemra/RoActemra
Genentech, Inc.
Multiple Myeloma
12/25
12/25
NCT05391750: Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Recruiting
1
72
US
Tocilizumab, Actemra, Immunoglobulin G1, Anti-(Human Interleukin 6 Receptor) (Human-Mouse Monoclonal MRA Heavy Chain), Disulfide with Human-Mouse Monoclonal MRA Kappa-Chain, Dimer, MRA, R-1569, RoActemra, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Emory University, National Cancer Institute (NCI)
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
02/26
02/27
NCT05091424: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recruiting
1
137
Europe, US, RoW
Mosunetuzumab, Lunsumio, Tocilizumab, Venetoclax, Venclyxto, Venclexta
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
05/27
10/29
WP42004, NCT04580121: A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Completed
1
59
Europe, Canada, US, RoW
RO7283420, Tocilizumab, Actemra, RoActemra, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine
Hoffmann-La Roche
Acute Myeloid Leukemia
08/23
08/23
CO43805, NCT05169515: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With Iberdomide and/or Golcadomide in Participants With B-Cell Non-Hodgkin Lymphoma

Recruiting
1
125
Europe, US, RoW
SC Mosunetuzumab, RO7030816, IV Glofitamab, RO7082859, Iberdomide, CC-220, Golcadomide, CC-99282, Obinutuzumab, RO5072759, Tocilizumab, RO4877533
Hoffmann-La Roche
Non-Hodgkin Lymphoma
03/27
03/29
NCT05927571: A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Recruiting
1
120
RoW
Cevostamab, Elranatamab, Tocilizumab
Genentech, Inc.
Relapsed or Refractory Multiple Myeloma
07/26
07/26
NCT05646836: A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Recruiting
1
90
Europe, RoW
Cevostamab, RO7187797, XmAb24306, RO7310729, Tocilizumab, Actemra, RoActemra
Genentech, Inc.
Multiple Myeloma
08/26
01/27
NCT05769959: Study of RO7515629 in Participants With HLA-G Positive Solid Tumors

Terminated
1
3
US
RO7515629, tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
03/24
03/24
NCT05835986: A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Recruiting
1
70
Europe, RoW
RO7507062, Tocilizumab, Actemra, RoActemra
Hoffmann-La Roche
Systemic Lupus Erythematosus
11/27
11/27
NCT05735366: A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

Recruiting
1
195
Japan, US
SAIL66
Chugai Pharmaceutical
Solid Tumor
12/28
12/28

Download Options